How has the alzheimer’s disease diagnostic market evolved, and where is it heading next?
The alzheimer’s disease diagnostic market size has grown rapidly in recent years. It will grow from $6.56 billion in 2024 to $7.28 billion in 2025 at a compound annual growth rate (CAGR) of 11%. The growth in the historic period can be attributed to rising prevalence of Alzheimer’s disease and dementia, growing awareness of the importance of early diagnosis for better management, advancements in imaging technologies, such as MRI and PET scans, increasing investment in research and development for neurodegenerative diseases, government initiatives and funding for Alzheimer’s research and diagnostics.
The alzheimer’s disease diagnostic market size is expected to see rapid growth in the next few years. It will grow to $10.91 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to development of blood-based biomarkers for non-invasive diagnosis, rising demand for personalized medicine and precision diagnostics, integration of AI and machine learning in diagnostic tools for early detection, growing adoption of digital health technologies for remote monitoring and diagnosis, expansion of healthcare infrastructure in emerging markets to improve accessibility. Major trends in the forecast period include emergence of multi-modal diagnostic approaches combining imaging, biomarkers, and cognitive tests, increasing focus on point-of-care diagnostic solutions for faster results, development of wearable devices for continuous monitoring of cognitive health, rising collaborations between biotech companies and research institutions for innovative solutions, growth in direct-to-consumer genetic testing for Alzheimer’s risk assessment.
Get Your Free Sample of The Global Alzheimer’s Disease Diagnostic Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp
What are the key drivers behind the rapid expansion of the alzheimer’s disease diagnostic market?
The increase in chronic disease is expected to propel the growth of the alzheimer’s disease diagnostic market going forward. Chronic disease is a chronic condition or chronic sickness, a health condition that persists or lasts for over three months. The increase in chronic disease is driven by the increased frequency of several interconnected factors, including lifestyle choices, environmental influences, genetic predisposition, and socioeconomic conditions. The presence of chronic conditions such as cardiovascular difficulties, diabetes, and hypertension increases the chance of acquiring Alzheimer’s disease (AD) and other kinds of dementia. For instance, in January 2022, according to a report shared by the American Heart Association Inc., a US-based nonprofit voluntary organization, brain disorders are expected to increase to 9.3 million in the US by 2060, and currently, this number is growing in the US. and one in every six people worldwide suffers from a brain disease. Currently, 1 billion people will suffer from brain disorders worldwide by 2021. Therefore, the increase in chronic disease will drive the growth of the alzheimer’s disease diagnostic market.
What is the segmentation for the alzheimer’s disease diagnostic market?
The alzheimer’s disease diagnostic market covered in this report is segmented –
1) By Type: Triage, Diagnosis, Screening
2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests
3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center
Subsegments:
1) By Triage: Cognitive Testing, Imaging Techniques
2) By Diagnosis: Biomarker Testing, Neuroimaging
3) By Screening: Neuropsychological Testing, Genetic Testing
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report
Who are the most influential companies in the alzheimer’s disease diagnostic market?
Major companies operating in the alzheimer’s disease diagnostic market are Pfizer Inc., AbbVie, Bristol Myers Squibb Company, Hoffmann-La Roche, Eli Lilly and Company, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Daiichi Sankyo Co., Sysmex, Lantheus, Quanterix, FujireBio, TauRx Pharmaceuticals Ltd, AC Immune, C2N diagnostics, AXON Neuroscience, Neuro-Bio Ltd, Anavex Life Sciences Corp., Treventis Corporation
What are the most influential trends expected to drive the alzheimer’s disease diagnostic market forward?
Major companies operating in the alzheimer’s disease diagnostic market are focusing on advancements of blood-based biomarker test which is expected to simplify the diagnostic process for Alzheimer’s disease, reducing reliance on more invasive procedures and improving access to timely treatment for patients. For instance, in October 2023, Quanterix, a US-based biotechnology research company, launched LucentAD p-Tau 217 test, a biomarker for Alzheimer’s pathology with clinical sensitivity and specificity in blood. Traditional approaches for cerebrospinal fluid (CSF) biomarkers include positron emission tomography (PET) or lumbar puncture, both of which are costly, invasive, and not widely available. Additionally, it combines Quanterix’s ultra-sensitive SimoaÒ technology with J&J Innovative Medicine’s well tested p-Tau 217 antibodies for excellent accuracy and a simpler process.
What are the major regional insights for the alzheimer’s disease diagnostic market, and which region holds the top position?
North America was the largest region in the alzheimer’s disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Alzheimer’s Disease Diagnostic Market Report 2025 Offer?
The alzheimer’s disease diagnostic market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Alzheimer’s disease diagnostics encompass methods and tools used to detect and confirm the presence of Alzheimer’s disease, a progressive neurodegenerative disorder. These diagnostics include cognitive assessments, imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, and biomarker tests analyzing cerebrospinal fluid (CSF) or blood for amyloid-beta and tau proteins.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21093
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
